1. Scrip
  3. >>Alimentary/Metabolic

Beam Picks Crowded AAT Field To Prove Its In Vivo Gene Editing

Base Editing Could Trump Existing Approaches

 
• By Andrew McConaghie

With its first US study for a base-edited CAR-T therapy now back on track, Beam Therapeutics is gearing up to begin studies of its first in vivo candidate, BEAM-302, next year in AAT.

Beam Therapeutics

Beam Therapeutics, a pioneer in the gene editing field of base editing, has unveiled early data from its first in vivo candidate, BEAM-302, which it hopes to take into the clinic next year.

While most competitors in the genetic therapy field are concentrating on ex vivo treatments, as these potentially carry less risk than making edits in the live human body, Beam is confident its in vivo platform could be

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Alimentary/Metabolic

More from Therapy Areas

Multiple Launches Help Lilly’s Japan Growth

 
• By Ian Haydock

Lilly saw solid growth for its business in Japan last year on the back of several new launches and is building its obesity and Alzheimer's portfolios in the country.

Novo Nordisk Looks To Septerna For Oral Obesity Options

 
• By Mary Jo Laffler

Deal Snapshot: The Danish drugmaker is partnering with GPCR drug discovery expert Septerna to develop multiple small molecules for cardiometabolic targets.

GSK Pays $1.2bn For Phase III-Ready MASH Contender

 
• By Andrew McConaghie

The acquisition of Boston Pharma’s once-a-month FGF21 analog adds to GSK’s liver disease portfolio.